Evening vs morning JAK inhibitor for rheumatoid arthritis
Official title: Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Run by Centre Hospitalier Princesse Grace · NCT07674134 · Data updated 2026-11-12
This observational study tests whether taking a JAK inhibitor in the evening works better than in the morning for adults with rheumatoid arthritis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Centre Hospitalier Princesse Grace Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Monaco) |
| Status | Recruiting |
| Started | April 23, 2024 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT07674134 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with rheumatoid arthritis starting a JAK inhibitor per label and recommendations.
✕Probably not a fit
Patients who do not respond differently to morning versus evening dosing or who do not complete follow-up may not experience a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares two once-daily dosing times for a JAK inhibitor prescribed for rheumatoid arthritis. Participants are adults meeting standard diagnostic criteria and starting a JAK inhibitor under the approved label. The study aims to see if evening dosing provides greater efficacy than morning dosing over six months. Data collected include treatment timing, responses, and safety, with follow-up conducted at planned intervals. No intervention beyond timing of administration is imposed.
Why it matters
Potential benefit: If evening dosing is more effective, patients may experience better symptom control with the same medication.
How similar studies have gone: Previous studies in similar settings have explored dosing time with mixed results; this study adds real-world observational data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged over 18 years * Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria * Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations * Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure. Exclusion Criteria: * No contraindication to a bDMARD * Not stable dose of corticosteroids in the 4 weeks preceding enrollment * Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment * Prior treatment with a JAK inhibitor * Patient unable to be followed-up in the study during 6 months * Minors or adults under guardianship or curatorship, or deprived of their liberty * Pregnant or breastfeeding patient * Patient refusing to use an effective method of contraception for the duration of the study * Person not affiliated with a social security scheme.
Where it's running
-
Centre Hospitalier Princesse Grace
Monaco, Monaco Recruiting
Study contacts
- Principal investigator: Olivier BROCQ, MD — Centre Hospitalier Princesse Grace
- Study coordinator: Olivier BROCQ, MD
- Email: recherche.clinique@chpg.mc
- Phone: 97 98 99 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.